NYSE$CNMD

Conmed Corp. · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Briefing

Reported positive first-quarter performance due to team's perseverance and increased full-year guidance.

CONMED Corporation announced positive first-quarter results, driven by the team's perseverance in a challenging environment. The company is increasing its full-year 2021 revenue guidance to between $1.0 billion and $1.03 billion and adjusted diluted net earnings per share to a range of $3.05 to $3.20.

  • CONMED's first-quarter performance was strong, reflecting the team's dedication.
  • The company is well-positioned to benefit from an improving surgical landscape.
  • Full-year 2021 revenue guidance has been raised to $1.0 to $1.03 billion.
  • Full-year 2021 adjusted diluted net earnings per share are now projected to be in the range of $3.05 to $3.20.

Headline financials

Total Revenue

$233M

Previous: $214M+8.7%
EPS (adj)

$0.63

Previous: $0.51+23.5%
Capital Expenditures

-$3.11M

Previous: -$2.83M-10.1%
Free Cash Flow

$6.75M

Previous: $3.1M+117.6%
Net Income

$9.86M

Previous: $5.93M+66.4%
Operating Income

$20.1M

Previous: $13.2M+52.5%
Gross Profit

$128M

Previous: $119M+7.8%
Cash & Equivalents

$36.8M

Previous: $24.3M+51.3%
Total Assets

$1.75B

Previous: $1.75B-0.2%
Stock-Based Comp

$3.39M

Previous: $3.03M+11.7%

Revenue & EPS history

Conmed · Revenue · Quarterly

$233M

Q1 2021+8.7%vs Q1 2020
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

Conmed · $277M total across 2 segments · Q2 2022

  • General Surgery
    $157M
  • Orthopedic Surgery
    $120M

Forward guidance

CONMED is increasing its guidance for full-year 2021 revenue and adjusted diluted net earnings per share.

Tailwinds

  • Revenue is expected to be between $1.0 billion and $1.03 billion.
  • Positive impact to 2021 sales from foreign exchange is expected.
  • Adjusted diluted net earnings per share in the range of $3.05 to $3.20.
  • Company is well-positioned to capitalize on an improving surgical landscape
  • Team’s ability to provide innovative solutions

Headwinds

  • Risks posed to the Company’s business, financial condition, and results of operations by the COVID-19 global pandemic
  • Deferral of surgeries
  • Reductions in hospital and ambulatory surgery center operating volumes
  • Disruption to potential supply chain reliability
  • General industry and economic conditions

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2021

Historical avgQ1 2021

-0.0%

Avg return

Earnings day

+0.4%

Avg return

5 days after

+3.0%

Avg return

30 days after

45%

29 / 65 earnings

Positive

+16.5%

Q1 2025

Best reaction

-18.5%

Q3 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.6%+1.9%-0.8%
Q4 2025-4.0%+0.3%+18.9%
Q3 2025-0.1%+0.6%-9.8%
Q1 2025+16.5%+13.8%+15.6%
Q4 2024-9.0%-12.1%-15.2%
Q3 2024+5.5%+9.0%+14.5%
Q2 2024-6.0%-5.6%+5.3%
Q1 2024-13.2%-5.7%+3.9%
Q4 2023-11.7%-13.0%-15.7%
Q3 2023-0.3%+3.1%+15.0%
Q2 2023-1.6%+0.8%-10.1%
Q1 2023+11.2%+9.2%+2.7%
Q4 2022+3.3%+6.4%+0.4%
Q3 2022-3.3%-1.0%+3.2%
Q2 2022-2.5%-4.5%-10.0%
Q1 2022-8.5%-19.2%-17.3%
Q4 2021+4.9%+11.0%+19.6%
Q3 2021+1.5%+2.0%-5.9%
Q2 2021+1.3%-0.2%-1.4%
Q1 2021+4.8%+7.0%+1.5%
Q4 2020-4.6%-6.1%+3.1%
Q3 2020+2.8%-3.9%+29.6%
Q2 2020+5.5%-0.4%+4.8%
Q1 2020+9.2%+0.5%+8.5%
Q4 2019-2.6%-4.7%-11.9%
Q3 2019+10.4%+12.9%+13.7%
Q2 2019+7.3%+4.5%+15.3%
Q1 2019+0.7%-2.6%+0.8%
Q4 2018+6.1%+4.9%+12.8%
Q3 2018-0.6%+1.3%+0.8%
Q2 2018+8.6%+5.5%+8.7%
Q1 2018+7.2%+5.3%+10.7%
Q4 2017+10.2%+7.1%+6.3%
Q3 2017+1.9%-2.7%+0.7%
Q2 2017-1.3%+1.3%-4.1%
Q1 2017+4.2%+6.9%+7.6%
Q4 2016-6.9%-4.0%-6.8%
Q3 2016+5.0%+3.3%+18.3%
Q2 2016-17.5%-16.9%-17.0%
Q1 2016-4.1%
Q4 2015-5.9%
Q3 2015-18.5%
Q2 2015-4.3%
Q1 2015+10.7%
Q4 2014-1.4%
Q3 2014+4.4%
Q2 2014-9.5%
Q1 2014-2.8%
Q4 2013+4.2%
Q3 2013-2.7%
Q2 2013+2.8%
Q1 2013-2.7%
Q4 2012+4.6%
Q3 2012+0.3%
Q2 2012-0.4%
Q1 2011+0.8%
Q1 2012-2.1%
Q1 2010-0.2%
Q4 2009-0.2%
Q4 2011-0.2%
Q3 2010-1.8%
Q3 2011-1.8%
Q2 2011-2.3%
Q4 2010-2.3%
Q2 2010-2.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro